NCT03317002View on ClinicalTrials.gov

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

April 8, 2020

Study Completion Date

April 8, 2020

Conditions
Coronary Artery Disease
Interventions
DRUG

AZD5718

Oral dose of AZD5718 (tablet)

DRUG

AZD5718

Oral dose of AZD5718 (tablet)

DRUG

Placebo

Matching placebo (tablet)

Trial Locations (9)

2000

Research Site, Frederiksberg

5000

Research Site, Odense C

8200

Research Site, Aarhus

20520

Research Site, Turku

70210

Research Site, Kuopio

75185

Research Site, Uppsala

413 45

Research Site, Gothenburg

222 42

Research Site, Lund

171 76

Research Site, Stockholm

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY